CDA | Evidence Driven
CDA | Evidence Driven

Icatibant Implementation Advice Panel

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0097-000 - SX0849-000

Canada’s Drug Agency is convening an implementation advice panel to advise the drug programs on funding criteria for icatibant for hereditary angioedema (HAE) with normal C1-inhibitor function (HAE nC1-INH), also known as type III HAE.

Files

Implementation Advice for Icatibant View PDF
Last Updated : December 16, 2024